×
More Charts Below
Veracyte Income from Continuous Operations 2012-2024 | VCYT
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Recent Trends
Veracyte income from continuous operations from 2012 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
Related Stocks
Company Name
Market
Cap
Intuitive Surgical (ISRG)
$171.9B
Thermo Fisher Scientific (TMO)
$161.4B
Alcon (ALC)
$45.6B
Edwards Lifesciences (EW)
$42B
IDEXX Laboratories (IDXX)
$33.3B
DexCom (DXCM)
$26.9B
IQVIA Holdings (IQV)
$25.4B
STERIS (STE)
$21.8B
Mettler-Toledo (MTD)
$20.9B
Waters (WAT)
$19.1B
SONOVA HOLDING (SONVY)
$17.3B
Fresenius Medical Care AG KGaA (FMS)
$13.9B
Hologic (HOLX)
$12.9B
Sysmex ADR (SSMXY)
$11.8B
Penumbra (PEN)
$10.7B
Globus Medical (GMED)
$9.8B
Masimo (MASI)
$8.2B
Teleflex (TFX)
$6B
Glaukos (GKOS)
$5.2B
Integer Holdings (ITGR)
$4.1B
TransMedics (TMDX)
$3B
PROCEPT BioRobotics (PRCT)
$2.9B
Nihon Kohden (NHNKY)
$2.1B
LivaNova (LIVN)
$1.9B
Elekta AB (EKTAY)
$1.9B
Alphatec Holdings (ATEC)
$1.5B
Integra LifeSciences Holdings (IART)
$1.2B
Pulse Biosciences (PLSE)
$1.2B
Tandem Diabetes Care (TNDM)
$1.1B
Paragon 28 (FNA)
$1.1B